SPOTLIGHT DISCUSSION - Rare diseases – under the microscope
Tuesday, November 17, 2020 2:30 PM to 3:05 PM
Enter full screen
Do current incentives match the difficulties companies face when developing orphan drugs? And is the reward proportionate to the benefits?
Is there a balance between the value of new orphan drugs and the cost?
What is the role of public investment in answering unmet needs?
Is there a risk the regulation developed for orphan drugs become the rule?